XPO Logistics Introduces Major New Benefits for Driver Trainees

Students receive full compensation and benefits during seven-week training, in addition to 100% paid tuition

GREENWICH, Conn. , July 08, 2021 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, has unveiled a roster of new benefits for participants in its driver training programs, effective immediately. XPO, a top three less-than-truckload (LTL) carrier in North America, has been providing professional driver training nationally for more than 35 years.

The company’s recent enhancements to student compensation and training options are designed to provide industry-best career paths, with access to schools in approximately 30 states and the flexibility to arrange local attendance. XPO driver trainees realize substantial value, including:

  • Comprehensive training in just seven weeks: five weeks of professional classroom instruction and two weeks of on-the-job experience with a mentor in the cab
  • Free tuition and a guaranteed wage paid for all 180 hours of classroom instruction and on-the-job training — a $10,000 value — plus the opportunity for paid dock work during the course of the program
  • A generous benefits package from day one of training, including full health insurance (medical, dental and vision), 401(k), life insurance, disability and more
  • An XPO job offer for students who successfully complete the program requirements
  • An accelerated compensation path for driver graduates in 85 US markets, ensuring a top pay rate after just one year of CDL-A experience

Josephine Berisha, chief human resources officer for XPO Logistics, said, “Our recent investments in LTL training will give more students an edge in becoming highly skilled drivers. We welcome all applicants with an interest in driving for XPO as an industry leader, including our non-driver employees who want to pursue a career behind the wheel.”

XPO trains over 700 student drivers on average each year, and expects to grow the number of graduates in 2021. The company is currently hiring to fill open positions for over 2,000 LTL drivers and dockworkers for its national service center network. Job opportunities and driver school openings can be found online at the XPO’s Careers Site.

About XPO Logistics

XPO Logistics, Inc. (NYSE: XPO) provides cutting-edge supply chain solutions to the most successful companies in the world, with two business segments: transportation and logistics. The company helps more than 50,000 customers manage their supply chains most efficiently, using a network of 1,621 locations in 30 countries and approximately 140,000 team members, including 108,000 employees and 32,000 temporary workers. The company’s corporate headquarters are in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on Facebook, Twitter, LinkedIn, Instagram and YouTube.

Media Contact

XPO Logistics, Inc. 
Joe Checkler 
+1-203-423-2098 
[email protected] 



VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors

TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021. Professor Ruth Arnon has stepped down from her role as a member of VBL’s Board of Directors, effective July 6, 2021. She will continue her engagement with VBL as a scientific consultant and a member of its Scientific Advisory Board.

“We are pleased to welcome Alison and Michael as the newest members of our Board of Directors,” said Bennett Shapiro, M.D., Chairman of VBL’s Board of Directors. “Alison’s extensive experience commercializing products globally at bluebird bio and Bristol-Myers Squibb and Michael’s expertise in healthcare capital markets will be invaluable to us as we approach disclosure of topline data from the OVAL clinical trial of VB-111 in platinum resistant ovarian cancer and, if successful, planning and execution of our strategic and operational objectives to bring VB-111 to patients who would benefit from it. We also owe a debt of gratitude to Prof. Ruth Arnon for her significant contributions to our development over 14 years of dedicated service on the Board.”

About Alison Finger

Ms. Finger has nearly three decades of biotech and pharmaceutical leadership experience building and optimizing brands and portfolios in the areas of genetic medicine, cell therapy, oncology, neurology, virology and metabolics. She has commercialized products in the U.S., Europe, Asia and other geographies. Most recently, Ms. Finger was Chief Commercial Officer at bluebird bio (bluebird), where she built the commercial infrastructure for Europe and the U.S. in advance of bluebird’s first gene and cell therapy product launches. Prior to bluebird, Ms. Finger spent 21 years at Bristol-Myers Squibb (BMS) leading the hematology/oncology, neurology, and virology franchises. In these roles, she led portfolio planning, brand and franchise commercial strategy, and supported Research and Development and Corporate Business Development decisions. Ms. Finger also served as Managing Director of BMS Australia/New Zealand and has managed country, regional, and global P&Ls. Previously, she was chair of the Alliance for Regenerative Medicine Gene Therapy Section and served on the Executive Board of the Alliance for Regenerative Medicine Foundation. She also was a member of the board for The Medicines Australia Industry Association, and a member of the Pharmaceutical Strategic Working Group for the Australia Senator for Industry and Innovation. Ms. Finger earned her B.A. from St. Lawrence University and an M.B.A. from Duke University’s Fuqua School of Business.

About Michael Rice

Mr. Rice has deep experience in portfolio management, investment banking, and capital markets. He is a Founding Partner at LifeSci Partners. Prior to founding LifeSci, Michael was the co-head of Health Care Investment Banking at Canaccord Adams, where he was involved in debt and equity financing. Mr. Rice was also a Managing Director at Think Equity Partners, where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions. Prior to that, he served as a Managing Director at Bank of America serving large hedge funds and private equity healthcare funds while working closely with Investment Banking. Previously, he was a Managing Director at JP Morgan/Hambrecht & Quist. He graduated from the University of Maryland and currently sits on the board of 9 Meters Biopharma Inc.

About the OVAL
S
tudy
(
NCT03398655
)
OVAL is an international Phase 3 randomized pivotal registration enabling clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum resistant ovarian cancer. The study is planned to enroll approximately 400 patients. OVAL is conducted in collaboration with the GOG Foundation, Inc., an independent international non-profit organization with the purpose of promoting excellence in the field of gynecologic malignancies.


About VB-111 (ofranergene obadenovec)
VB-111 is an investigational anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is a unique biologic agent that is designed to use a dual mechanism to target solid tumors. Its mechanism combines blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 has received an Orphan Designation for the treatment of ovarian cancer from the European Commission. VB-111 has also received orphan drug designation in both the US and Europe, and fast track designation in the US, for prolongation of survival in patients with recurrent glioblastoma. VB-111 demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer (NCT01711970).

About VBL
Therapeutics

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL Therapeutics has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL Therapeutics’s lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL Therapeutics-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

CONTACT:

Burns McClellan for VBL Therapeutics

Lee Roth (investors) / Ryo Imai (media)
[email protected] / [email protected]  
+1-212-213-0006



Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a panel discussing next-generation approaches to targeted oncology at the upcoming virtual William Blair Biotech Focus Conference.

Details on the panel webcast can be found below.

        Date: Thursday, July 15, 2021
        Time: 9:00 – 9:45 a.m. ET
        Webcast Link: Register

The panel will be webcast live and can be accessed by visiting the Investors & Media section of the company’s website at www.ikenaoncology.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Ikena Oncology

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs. To learn more visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

Media Contact:

Gwen Schanker
LifeSci Communications
[email protected]

Investor Contact:
Rebecca Cohen
Ikena Oncology
[email protected]



Laredo Petroleum Provides Second-Quarter 2021 Operational Update and Revised 2021 Capital Budget and Production Guidance

TULSA, OK, July 08, 2021 (GLOBE NEWSWIRE) — Laredo Petroleum, Inc. (NYSE: LPI) (“Laredo” or the “Company”) today provided preliminary production results and an operational update for the second quarter of 2021 and its revised capital budget and production guidance for full-year 2021 in association with the closing of the acquisition of the Howard County leasehold of Sabalo Energy, LLC (“Sabalo”) and the divestiture of legacy proved developed producing reserves.

Second-Quarter 2021 Operational Update
In the second quarter of 2021, Laredo produced approximately 85.9 thousand barrels of oil equivalent (“BOE”) per day, including oil production of approximately 26.4 thousand barrels of oil per day (“BOPD”), growing both total and oil production by 9% versus first-quarter 2021.

In mid-to-late June, the Company’s production operations in Howard County were impacted by a combination of delayed third-party connections to tank batteries, downtime at third-party facilities due to weather-related events and lost power in the field. For approximately 10 days, Laredo chose to curtail production to minimize flaring rather than continue producing crude oil at maximum rates and flaring excessive amounts of wet gas. Laredo estimates that the curtailments and shut-ins reduced second-quarter 2021 total production by approximately 900 BOE per day, including approximately 700 BOPD of oil production. The midstream infrastructure and field electrical issues have been addressed and production operations in Howard County have returned to normal.

Incurred capital expenditures in the second quarter of 2021 were approximately $100 million, excluding non-budgeted acquisitions and a $10 million leasehold expenditure. Laredo completed 16 wells during second-quarter 2021, three more than anticipated, as reductions in the time to drill and complete wells pulled activity from the third quarter of 2021 into the second quarter. The 13-well Davis package was put on production during the second half of the quarter and the three additional completions are part of the 12-well West package, with the remaining nine wells in the West package expected to begin flowing back during the third quarter of 2021.

Revised Full-Year 2021 Capital Budget and Production Guidance
The Company’s revised full-year 2021 capital budget is driven by the integration of Sabalo’s operations into Laredo’s low-cost operational structure paired with continued efficiency gains. The revised budget achieves a 22% increase in completed wells and a 24% increase in completed lateral feet versus the previous budget while investing only 17% more capital. Revised production guidance reflects the sale of approximately 25,000 BOE (23% oil) per day of gas-weighted production from the Company’s legacy leasehold and the purchase of approximately 13,600 BOE (89% oil) per day of production from Sabalo, as of July 1, 2021.

    FY-21E Revised   FY-21E Previous
Production and capital:        
Total production (MBOE per day)     77.0 – 80.0       80.0 – 85.0  
Oil production (MBOPD)     30.5 – 31.5       27.3 – 29.3  
Incurred capital expenditures, excluding non-budgeted acquisitions ($ MM)   $ 420     $ 360  
         
Selected activity metrics:        
Spuds     64       53  
Completions     67       55  
Working interest     100 %     100 %
Average lateral length (feet)     10,000       9,800  
                 

Preliminary 2022 Operational Plan
By the second quarter of 2022, Laredo expects to return to a highly-efficient operational cadence of two rigs and one completions crew. Current plans are for total capital expenditures, including infrastructure and other capitalized costs, excluding non-budgeted acquisitions, of approximately $380 million and to complete approximately 60 wells with an average lateral length of approximately 11,500 feet during full-year 2022. This activity level is expected to generate oil production of 36,000 to 38,000 BOPD for full-year 2022, holding oil production approximately flat versus the expected fourth-quarter 2021 exit rate. Total production is expected to average 75,000 to 78,000 BOE per day, a slight decline in total production versus full-year 2021. At current 2022 commodity prices, the Company expects this plan to generate $225 million to $250 million of Free Cash Flow1.

“During the second quarter, Laredo again executed on its Howard County development plan,” stated Jason Pigott, President and Chief Executive Officer. “Our team quickly made up lost time from the storms in the first quarter and got ahead of schedule by the end of the second quarter. When we experienced some production issues associated with our third-party midstream and electrical providers, we took the necessary steps to curtail production and demonstrated our commitment to minimizing flaring and properly stewarding our resources.”

“As we integrate Sabalo’s operations, we have budgeted a moderate increase in activity and capital levels for the remainder of 2021, primarily driven by the drilling and completion of an eight-well package that was already in process at the closing of the transaction,” continued Mr. Pigott. “We remain committed to a disciplined development pace and expect to return to operating two drilling rigs and one completions crew in early 2022. At this pace, the capital efficiency of our Howard County acreage is expected to drive significant, sustainable Free Cash Flow1 generation while keeping oil production relatively flat with our 2021 exit rate. We expect to utilize our Free Cash Flow1 to reduce debt and push our leverage down to 1.5 times by the end of 2022.”


Forward-Looking Statements


This press release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities that Laredo assumes, plans, expects, believes, intends, projects, indicates, enables, transforms, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements. The forward-looking statements are based on management’s current belief, based on currently available information, as to the outcome and timing of future events. Such statements are not guarantees of future performance and involve risks, assumptions and uncertainties.

General risks relating to Laredo include, but are not limited to, the decline in prices of oil, natural gas liquids and natural gas and the related impact to financial statements as a result of asset impairments and revisions to reserve estimates, the ability of the Company to execute its strategies, including its ability to successfully identify and consummate strategic acquisitions at purchase prices that are accretive to its financial results and to successfully integrate acquired businesses, assets and properties, oil production quotas or other actions that might be imposed by the Organization of Petroleum Exporting Countries and other producing countries (OPEC+), the outbreak of disease, such as the coronavirus (COVID-19) pandemic, and any related government policies and actions, changes in domestic and global production, supply and demand for commodities, including as a result of the COVID-19 pandemic and actions by OPEC+, long-term performance of wells, drilling and operating risks, the increase in service and supply costs, tariffs on steel, pipeline transportation and storage constraints in the Permian Basin, production curtailment, hedging activities, possible impacts of litigation and regulations, the impact of repurchases, if any, of securities from time to time and other factors, including those and other risks described in its Annual Report on Form 10-K for the year ended December 31, 2020, its Current Report on Form 8-K filed on May 11, 2021 and those set forth from time to time in other filings with the SEC. These documents are available through the SEC’s Electronic Data Gathering and Analysis Retrieval System at www.sec.gov. Any of these factors could cause Laredo’s actual results and plans to differ materially from those in the forward-looking statements. Therefore, Laredo can give no assurance that its future results will be as estimated. Laredo does not intend to, and disclaims any obligation to, update or revise any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.



1



Free Cash Flow (Unaudited)


Free Cash Flow is a non-GAAP financial measure that the Company defines as net cash provided by operating activities (GAAP) before changes in operating assets and liabilities, net, less costs incurred, excluding non-budgeted acquisitions. Free Cash Flow does not represent funds available for future discretionary use because it excludes funds required for future debt service, capital expenditures, acquisitions, working capital, income taxes, franchise taxes and other commitments and obligations. However, management believes Free Cash Flow is useful to management and investors in evaluating operating trends in its business that are affected by production, commodity prices, operating costs and other related factors. There are significant limitations to the use of Free Cash Flow as a measure of performance, including the lack of comparability due to the different methods of calculating Free Cash Flow reported by different companies.

Investor Contact:
Ron Hagood
918.858.5504
[email protected]



Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day

Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory drugs utilizing spherical nucleic acid (SNA™) technology, will host a virtual R&D Day on Thursday, July 15, 2021 from 10:00 am to 11:00 am ET. The event will showcase Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia (FA), XCUR-FXN, which is designed to address the underlying molecular cause of FA.

Exicure will present new and previously unreleased preclinical data and discuss progress with XCUR-FXN, which is on track for IND filing in late Q4 2021. Additionally, Exicure will discuss its perspective on XCUR-FXN’s competitive differentiation in FA and the program’s path to clinical validation.

Also, Exicure will provide an update on its expanding pipeline across several rare neurodegenerative diseases of high unmet need and highlight progress with two preclinical programs targeting SCN9A (Nav1.7) for neuropathic pain and CLN3 for Batten Disease.

“We believe that our SNA platform is ideally suited to address neurological disorders based on the demonstrated ability of SNAs in nonclinical studies to achieve higher cellular uptake in all key cell types and broad biodistribution in the CNS, including deep brain regions,” says Dr. David Giljohann, Exicure’s CEO. “We are excited to translate our platform’s capabilities to potential benefits for patients as demonstrated by our bi-specific SNA, XCUR-FXN for Friedreich’s Ataxia, anticipated to enter the clinic in the first half of 2022.”

A live webcast will be available in the Events and Presentations section of Exicure’s website on July 15, 2021 at 10:00 am ET. An archived version will be available on the company website following the event. Additional information can be found here: https://event.on24.com/wcc/r/3305687/FA6C43097DA849A64659B1FB63A8C259

About Friedreich’s Ataxia

Friedreich’s Ataxia is the most commonly inherited ataxia, a degenerative neuromuscular disease leading to progressive loss of coordination and causing severe childhood disability and early mortality, in most cases before age 40. It is a monogenic disorder caused by mutations in the FXN gene resulting in reduced levels of frataxin protein. FA affects about 13,500 people in the US, Europe, Canada, and Australia combined. There are currently no approved therapies for Friedreich’s Ataxia patients.

About SCN9A

SCN9A is the gene encoding Nav1.7, a trans-membrane sodium channel, that plays a critical role in pain signal signaling. Nav1.7 is strongly expressed in dorsal root ganglion (DRG) neurons, which mediate transmission of peripheral pain signals to the brain. Nav1.7’s critical role for pain signaling has been biologically validated by human gain-of-function mutations leading to severe pain conditions such as Inherited Erythromelalgia and Small Fiber Neuropathy and human loss-of-function mutations lead to congenital insensitivity to pain. Nav1.7-targeting therapies could provide a novel treatment option for neuropathic pain conditions in which currently available therapies are largely ineffective.

About CLN3 Batten Disease

CLN3 Batten Disease is a monogenic, autosomal recessive, lysosomal storage disorder caused by mutations in the CLN3 gene resulting in batten protein deficiency. Affected individuals experience childhood blindness, pediatric dementia syndrome, seizures, and early death between age 20 and 30. CLN3 Batten is estimated to affect greater than 1,800 individuals in the United States and Europe. There are currently no approved therapies for these patients.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure’s drug candidate cavrotolimod (AST-008) is currently in a Phase 2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.

For more information, visit Exicure’s website at www.exicuretx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact could be deemed forward looking including, but not limited to, statements regarding the advancement of the Company’s clinical programs and its expansion into neuroscience; its clinical development of XCUR-FXN including developmental and regulatory submission timelines and anticipated data read-outs; and the timing and success of its preclinical programs including a program targeting SCN9A for neuropathic pain and a program targeting CLN3 Batten Disease. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risks that the ongoing COVID-19 pandemic may disrupt the company’s business and/or the global healthcare system more severely than it has to date or more severely than anticipated, which may have the effect of impacting or delaying the company’s ongoing Phase 1b/2 clinical trial; unexpected costs, charges or expenses that reduce the company’s capital resources; the company’s preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of the company to protect its intellectual property rights. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by the company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the company undertakes no duty to update this information, except as required by law.

For Media:

Karen Sharma

MacDougall

781-235-3060

[email protected]

KEYWORDS: United States North America Illinois Massachusetts

INDUSTRY KEYWORDS: Science Other Science Research Pharmaceutical Oncology Health Genetics Other Health

MEDIA:

Logo
Logo

AGTC to Host Virtual R&D Day on July 22, 2021

Widely Recognized Experts and AGTC Leadership Will Expand on Recent ACHM Phase 1/2 Clinical Trial Data and Discuss XLRP Milestones

Webcast Scheduled from 10:00 am – 1:00 pm ET

GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will host a virtual R&D Day from 10:00 am to 1:00 pm ET on Thursday, July 22, 2021.

AGTC’s R&D Day will include a review of 12-month data from the highest dose groups in the ongoing Phase 1/2 clinical trials in X-linked retinitis pigmentosa (XLRP), which the Company announced in May, and expanded analysis of the recently reported data from the Company’s ongoing Phase 1/2 clinical trial in achromatopsia (ACHM). The event also will include a discussion on light sensitivity and achromatopsia genetics, and an overview of the Company’s manufacturing capabilities, including the 21,000 square foot current Good Manufacturing Practices (cGMP) manufacturing and quality control facility being built in Florida.

“AGTC has seen highly encouraging 12-month data from our XLRP and ACHM clinical trials over the last two months, which gives us confidence in our abilities to execute the clinical and regulatory steps necessary to advance those therapies,” said Sue Washer, President and Chief Executive Officer of AGTC. “We look forward to taking a deeper dive into this data during our R&D Day and discussing preparations for late-stage development of our ACHM and XLRP candidates.”

AGTC R&D Day Agenda:

  • Corporate Overview

    • Sue Washer, President & Chief Executive Officer
  • Pre-Clinical Pipeline

    • Adrian Timmers, Executive Director, In vivo Pharmacology and Toxicology
  • Manufacturing and New Facility Update

    • Dave Knop, PhD, Vice President of Process Development
    • Stephen Potter, Chief Business Officer
  • XLRP Indication, Phase 1/2 Data

    • Robert Sisk, MD – Associate Professor of Ophthalmology, University of Cincinnati and Cincinnati Eye Institute, XLRP Phase 1/2 clinical trial investigator
  • ACHM Indication, Phase 1/2 Data

    • Rachel Huckfeldt, MD, PhD, Assistant Professor of Ophthalmology, Harvard Medical School Department of Ophthalmology, Director, Inherited Retinal Degenerations Fellowship, Massachusetts Eye and Ear Infirmary
  • Light Sensitivity and Achromatopsia Genetics

    • Joseph Carroll, PhD – Richard O. Schultz, MD / Ruth Works Professor of Ophthalmology Professor of Ophthalmology & Visual Sciences, Biophysics, and Cell Biology, Neurobiology and Anatomy Director, Advanced Ocular Imaging Program

A live audio webcast of the presentation with accompanying slides can be accessible by visiting ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. 

Those interested in attending can RSVP by clicking the RSVP link in the Events & Presentations page of the investor section at AGTC.com.

The archived webcast and slide presentation will be available in the Events and Presentations section of the Company’s website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR CONTACTS:

David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
[email protected] or [email protected]

Corporate Contact:

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
[email protected]



Mesa Air Group Reports June 2021 Operating Performance

PHOENIX, July 08, 2021 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) today reported Mesa Airlines’ operating performance for June 2021.

Mesa Airlines reported 30,015 block hours in June 2021, a 224.6 percent increase from June 2020 as a result of increased flying due to industry recovery from the COVID-19 pandemic. The Company also reported a controllable completion factor of 98.58 percent and 99.97 percent for its American and United operations, respectively.

Operating statistics for June 2021 and fiscal year 2021 YTD are included in the table below.

  Jun-21   Jun-20   % Change     YTD FY2021   YTD FY2020   % Change  
Block Hours              
American 12,610   3,000   320.4 %   98,549   111,199   -11.4 %
United 17,184   6,248   175.0 %   128,129   144,289   -11.2 %
DHL 221   n/a   N/A     1,673   n/a   N/A  
Total 30,015   9,247   224.6 %   228,351   255,488   -10.6 %
               
  Jun-21   Jun-20   % Change     YTD FY2021   YTD FY2020   % Change  
Departures              
American 7,020   1,699   313.2 %   51,934   63,693   -18.5 %
United 7,712   3,550   117.2 %   59,984   72,559   -17.3 %
DHL 144   n/a   N/A     1,086   n/a   N/A  
Total 14,876   5,249   183.4 %   113,004   136,252   -17.1 %
               
  Jun-21   Jun-20   % Change     YTD FY2021   YTD FY2020   % Change  
Controllable

Completion

Factor*
         
American 98.58 % 100.00 % -1.42 %   99.67 % 99.75 % -0.08 %
United 99.97 % 100.00 % -0.03 %   99.98 % 99.98 % 0.00 %
               
Total Completion Factor**              
American 96.83 % 100.00 % -3.17 %   97.00 % 93.27 % 4.00 %
United 98.76 % 99.83 % -1.07 %   97.62 % 94.72 % 3.06 %

Operating statistics month over month for the third quarter of fiscal year 2021 and QTD are included in the table below.

  Jun-21   May-21   % Change     QTD FY2021   QTD FY2020   % Change  
Block Hours              
American 12,610   11,741   7.4 %   35,417   14,532   143.7 %
United 17,184   16,300   5.4 %   49,127   17,090   187.5 %
DHL 221   223   -1.1 %   617   n/a   N/A  
Total 30,015   28,264   6.2 %   85,162   31,622   169.3 %
               
  Jun-21   May-21   % Change     QTD FY2021   QTD FY2020   % Change  
Departures              
American 7,020   6,368   10.2 %   19,586   8,316   135.5 %
United 7,712   7,482   3.1 %   22,397   9,776   129.1 %
DHL 144   143   0.7 %   407   n/a   N/A  
Total 14,876   13,993   6.3 %   42,390   18,092   134.3 %
               
  Jun-21   May-21   % Change     QTD FY2021   QTD FY2020   % Change  
Controllable

Completion

Factor*
         
American 98.58 % 99.84 % -1.3 %   99.42 % 100.00 % -0.6 %
United 99.97 % 100.00 % 0.0 %   99.98 % 100.00 % -0.02 %
               
               
Total Completion Factor**              
American 96.83 % 97.22 % -0.4 %   97.57 % 78.50 % 24.3 %
United 98.76 % 99.27 % -0.5 %   99.21 % 84.77 % 17.0 %

*Controllable Completion Factor excludes cancellations due to weather and air traffic control

**Total Completion Factor includes all cancellations

About Mesa Air Group, Inc.

Headquartered in Phoenix, Arizona, Mesa Air Group, Inc. is the holding company of Mesa Airlines, a regional air carrier providing scheduled passenger service to 116 cities in 36 states, the District of Columbia, and Mexico as well as cargo services out of Cincinnati/Northern Kentucky International Airport. As of June 30, 2021, Mesa operated a fleet of 165 aircraft with approximately 470 daily departures and 3,100 employees. Mesa operates all of its flights as either American Eagle, United Express, or DHL Express flights pursuant to the terms of capacity purchase agreements entered into with American Airlines, Inc., United Airlines, Inc., and DHL.

Investor Relations
Susan Donofrio
[email protected]

Media
Megan Bilbao
[email protected]



KKR to Acquire Leading Home Services Platform Neighborly®

KKR to Acquire Leading Home Services Platform Neighborly®

NEW YORK–(BUSINESS WIRE)–
KKR, a leading global investment firm, announced today that it has agreed to acquire Neighborly® (the “Company”), the world’s largest provider and franchisor of home service brands, from Harvest Partners. Financial details of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005304/en/

Founded in 1981, Neighborly® is a leading home services platform that connects more than 10 million residential and commercial customers with a community of professional services focused on repairing, maintaining and enhancing consumers’ homes and properties. Through a portfolio of 28 brands, the Company offers a wide array of services including plumbing, pest control, restoration, electrical, cleaning, HVAC, home inspection and many more.

As one of the largest franchisors of ‘do-it-for-me’ professional services, Neighborly® has built a network of more than 4,800 franchises both in the U.S. and internationally. Over the past decade, the Company has quickly grown its platform through the organic growth of its existing service brands and strategic acquisitions of complementary franchise service brands.

Mike Bidwell, President and CEO of Neighborly®, said, “Today’s milestone is a strong validation of our business-building strategy and differentiated ability to deliver essential home services. We are excited to embark on our next chapter of growth with KKR’s support and global expertise and look forward to continuing to be a partner of choice for both customers and franchise owners in the years to come.”

Felix Gernburd, Managing Director at KKR, said, “In a large and highly fragmented industry, Neighborly stands out for its differentiated strategy of bringing together adjacent services under a diversified and tech-enabled platform, and – most importantly – for its unrivaled dedication to customer service. We are thrilled to be investing in the Neighborly team as they continue to execute on their mission: enriching people’s lives by delivering amazing experiences.”

Nicholas Romano, Partner at Harvest Partners, said, “We are pleased to have worked with Mike and his team to continue building the premier residential service provider providing services that consumers need to repair, maintain and enhance their homes. Thoughtful investments in technology and human capital have resulted in a platform positioned for accelerated growth in the coming years.” Harvest’s Neighborly investment team is led by Steve Eisenstein, Nicholas Romano and David Schwartz.

KKR is making the investment in Neighborly® from its North American private equity fund.

Harris Williams is acting as financial advisor to Neighborly®, with White & Case acting as a legal advisor on the transaction.

The transaction is expected to close in Q3 2021, subject to regulatory approvals and other customary closing conditions.

About Neighborly®

Neighborly® is the world’s largest home services franchisor of 28 brands and more than 4,800 franchises collectively serving 10 million+ customers in nine countries, focused on repairing, maintaining and enhancing homes and businesses. The company operates online platforms that connect consumers to service providers in their local communities that meet their rigorous standards as a franchisor across 18 service categories at Neighborly.com in the United States and Neighbourly.ca in Canada. More information about Neighborly/Neighbourly, and its franchise concepts, is available at https://www.neighborlybrands.com/. To learn about franchising opportunities with Neighborly®, click here.

About KKR

KKR is a leading global investment firm that offers alternative asset management and capital markets, and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit, and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life, and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

About Harvest Partners

Founded in 1981, Harvest Partners is an established New York-based private equity firm that focuses on investments in middle-market companies in the business services & industrial services, consumer, healthcare, industrials and software industries. This strategy leverages Harvest’s 40 years of experience in financing organic and acquisition-oriented growth companies. For more information, please visit www.harvestpartners.com.

For Neighborly:

Loren Brown

+1 817 913-0194

[email protected]

For KKR:

Cara Major or Miles Radcliffe-Trenner

+1 212 750-8300

[email protected]

For Harvest Partners:

Catherine Clifford

+1 212 599-6300

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Software Construction & Property Finance Building Systems Professional Services Technology Residential Building & Real Estate

MEDIA:

Logo
Logo
Logo
Logo

GasLog Partners LP Announces Chief Executive Officer and Director Transition

Piraeus, Greece, July 08, 2021 (GLOBE NEWSWIRE) — GasLog Partners LP (“GasLog Partners” or the “Partnership”)(NYSE: GLOP) today announced senior management and board of director changes. The board of directors of GasLog Partners (the “Board”) is pleased to appoint Paolo Enoizi, currently Chief Operating Officer (“COO”) of the Partnership’s General Partner, GasLog Ltd. (“GasLog” and together with GasLog Partners, the “Group”), and GasLog Partners, as Chief Executive Officer (“CEO”) of the Partnership, effective August 1, 2021. Mr. Enoizi will continue to serve as COO of GasLog and GasLog Partners following his appointment as CEO of GasLog Partners. Paul Wogan will step down from his position as the Partnership’s CEO on July 31, 2021; however, he will remain CEO of GasLog.

In addition, GasLog Partners announced changes to the Board. Paul Wogan will step down as Director of the Partnership, effective July 31, 2021. GasLog, the Partnership’s General Partner, has appointed Paolo Enoizi as Director of the Partnership, effective August 1, 2021.

Curt Anastasio, Chairman of GasLog Partners, said, “We are delighted to be welcoming Paolo as our new CEO. Since joining as COO in 2019 Paolo has been leading the effort to improve the operational efficiency and competitiveness of the Group’s fleet. His depth of knowledge and experience in shipping and ship operations make him ideally suited to lead the Partnership as we look to maximize the value of our vessels trading in the short-term market.

On behalf of the Board, I want to thank Paul for his contributions to the Partnership, particularly given the uncertain backdrop we’ve had to navigate over the last 12 months.”

Paul Wogan said, “I have really enjoyed serving as the Partnership’s CEO and I am pleased to be handing leadership of GasLog Partners to Paolo. His proven track record of delivering operational excellence will continue to be instrumental in ensuring the Partnership’s future competitiveness. I wish Paolo great success in his expanded role.”

Paolo Enoizi commented, “I am excited to be taking over as CEO of the Partnership during this time of transition. I look forward to working with my colleagues and the Board as we develop an independent strategy that aims to make the Partnership a leader in its markets.”

Contacts:

Joseph Nelson
Head of Investor Relations
Phone: +1 212-223-0643

Email: [email protected]


About GasLog Partners

GasLog Partners is a growth-oriented owner, operator and acquirer of LNG carriers. The Partnership’s fleet consists of 15 LNG carriers with an average carrying capacity of approximately 158,000 cbm. GasLog Partners is a publicly traded master limited partnership (NYSE: GLOP) but has elected to be treated as a C corporation for U.S. income tax purposes and therefore its investors receive an Internal Revenue Service Form 1099 with respect to any distributions declared and received. The Partnership’s principal executive offices are located at 69 Akti Miaouli, 18537, Piraeus, Greece. Visit GasLog Partners’ website at http://www.gaslogmlp.com.



Armstrong Flooring Announces Date for Second Quarter 2021 Results

LANCASTER, Pa., July 08, 2021 (GLOBE NEWSWIRE) — Armstrong Flooring, Inc. (NYSE: AFI) (“Armstrong Flooring” or the “Company”), a leader in the design and manufacture of innovative flooring solutions, announced today that the Company will release its second quarter 2021 financial results before the market opens on Wednesday, July 21, 2021. A webcast and conference call will be held that same day at 10:00 a.m. Eastern Time to review financial results, discuss recent events and conduct a question-and-answer session.

Webcast and Conference Call:

The live webcast will be available through the “Investor Relations” section of the Company’s website, www.armstrongflooring.com. Participants are advised to go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software. For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-877-407-0789 or 1-201-689-8562, respectively. Upon dialing in, please request to join the Armstrong Flooring Second Quarter 2021 Earnings Conference Call.

About Armstrong Flooring

Armstrong Flooring, Inc. (NYSE: AFI) is a global leader in the design and manufacture of innovative flooring solutions that inspire beauty wherever your life happens. Headquartered in Lancaster, Pennsylvania, Armstrong Flooring continually builds on its resilient, 150-year legacy by delivering on its mission to create a stronger future for customers through adaptive and inventive solutions. The company safely and responsibly operates seven manufacturing facilities globally, working to provide the highest levels of service, quality, and innovation to ensure it remains as strong and vital as its 150-year heritage. Learn more www.armstrongflooring.com.

Contact Information

Investors:
Amy Trojanowski
SVP, Chief Financial Officer
[email protected]

Media:
Alison van Harskamp
Director, Corporate Communications
[email protected]